LLY — Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 47,000
- Website: https://www.lilly.com
Latest SEC filings for LLY
- 10-Q — 2026-08-05
- 8-K — 2026-08-05
- 11-K — 2026-06-23
- 8-K — 2026-05-20
- SD — 2026-05-11
- 424B2 — 2026-05-08
- 8-K — 2026-05-07
- FWP — 2026-05-06
- 424B2 — 2026-05-06
- 8-K — 2026-04-30
Latest LLY news
- — The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It. (The Motley Fool)
- — Eli Lilly releases promising early-stage data on ADC for ovarian cancer (seekingalpha_market)
- — 3 Portfolio-Worthy Stocks Hitting 52-Week Highs: AAPL, LLY & KO (Zacks Investment Research)
- — 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) (The Motley Fool)
- — Facing Investing Fears (The Motley Fool)
- — AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks Investment Research)
- — Why Healthcare ETFs Are Hovering Around One-Year Highs (Zacks Investment Research)
- — Should Defiance Large Cap ex-Mag 7 ETF (XMAG) Be on Your Investing Radar? (Zacks Investment Research)
- — Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances (Zacks Investment Research)
- — Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight (GlobeNewswire Inc.)
Educational tool only — not investment advice.